质子泵抑制剂对服用阿司匹林联合氯吡格雷急性冠脉综合征患者净临床不良事件发生风险影响 : = Effect of proton pump inhibitors on the risk of net clinical adverse events in patients with acute coronary syndrome receiving aspirin combined and clopidogrel
目的探讨质子泵抑制剂(PPIs)对服用阿司匹林联合氯吡格雷的急性冠脉综合征(ACS)患者净临床不良事件(NACE)发生风险的影响。方法选取自2012年1月至2014年3月一项前瞻性、多中心、大规模注册登记研究冠心病抗血小板治疗优选方案(OPT-CAD)入选的服用氯吡格雷联合阿司匹林满1年的5 228例ACS患者为研究对象。根据是否服用了PPIs,将所有患者分为联用PPIs组(n=1 816)与未联用PPIs组(n=3 412)。以12个月内的净临床不良事件(NACE,包括全部心肌梗死、缺血性卒中和全部的出血事件的复合终点)为主要终点,以12个月内的NACE事件的组成成分以及出血学术研究联合会(BARC)定义的出血事件(BARC 2～5型)为次要终点。比较两组患者一般资料、出院后用药情况及临床结局。结果联用PPIs组患者年龄、估计的肾小球滤过率、左室射血分数及消化系统病史、消化道溃疡比例要高于未联用PPIs组,两组比较,差异均有统计学意义(P<0.05)。联用PPIs组的β受体阻滞剂和血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂的使用比例要高于未联用PPIs组,两组比较,差异均有统计学意义(P<0.05)。两组患者12个月NACE事件发生率、12个月缺血事件、心肌梗死、缺血性卒中、全部出血、BARC 2～5型出血方面比较,差异均无统计学意义(P>0.05)。结论 PPIs对服用阿司匹林联合氯吡格雷的ACS患者NACE发生风险没有影响。.
Objective To investigate the effect of proton pump inhibitors(PPIs)on net adverse clinical events(NACE)in patients with acute coronary syndrome(ACS)receiving aspirin and clopidogrel.Methods From January 2012 to March 2014,5 228 ACS patients who had been taking clopidogrel combined with aspirin for one year and who were enrolled in the optimal antiplatelet therapy for coronary heart disease(OPT-CAD)in a prospective,multi-center,large-scale registry study were selected as subjects.All patients were divided into the combination PPIs group(n=1 816)and not combination PPIs group(n=3 412)according to whether PPIs was administered.The primary end point was the NACE(including myocardial infarction,stroke,and all bleeding and major bleeding) within 12 months,and the secondary end point was the components of NACE events within 12 months and bleeding events(BARC type 2-5)defined by the academic research consortium(BARC).General data,drug use after discharge and clinical outcomes were compared between the two groups.Results Age,estimated glomerular filtration rate,left ventricular ejection fraction,history of digestive system,peptic ulcer rate in the combination PPIs group were higher than those in the not combination PPIs group,and the differences between the two groups were statistically significant(P<0.05).Beta blockers and angiotensin converting enzyme inhibitor/angiotensin Ⅱ receptor blockers use ratio in the combination PPIs group was higher than that in the not combination group(P<0.05).There were no statistically significant differences between the two groups in 12-month NACE event incidence,12-month ischemic event,myocardial infarction,ischemic stroke,total hemorrhage and BARC type 2-5 hemorrhage(P>0.05).Conclusion PPIs do not effect the risk of NACE in ACS patients treated with aspirin and clopidogrel..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-05-15 2019 |
|---|---|
| Erschienen: |
2019-05-15 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
Lin chuang jun yi za zhi - (2019), 05 vom: 15. Mai, Seite 463-465+471 Original Letters: Enthalten in 临床军医杂志 (DE-600)2990629-5 (DE-600)2990629-5 辽宁省沈阳市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Effect of proton pump inhibitors on the risk of net clinical adverse events in patients with acute coronary syndrome receiving aspirin combined and clopidogrel |
|---|
| Beteiligte Personen: |
范鹏 [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Anmerkungen: |
Author info:FAN Peng;LI Yi;WANG He-yang;LI Jing;QIU Miao-han;ZHAO Wei-chao;FANG Chu-ai;HAN Ya-ling;School of Life Sciences and Biopharmaceutics,Shenyang Pharmaceutical University |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ630735409 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ630735409 | ||
| 003 | DE-627 | ||
| 005 | 20230120075603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230102s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ630735409 | ||
| 035 | |a (SBB-XA)CAJ_JYGZ201905007 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R541.4 |2 clc | ||
| 100 | 0 | |a 范鹏 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 质子泵抑制剂对服用阿司匹林联合氯吡格雷急性冠脉综合征患者净临床不良事件发生风险影响 |b = Effect of proton pump inhibitors on the risk of net clinical adverse events in patients with acute coronary syndrome receiving aspirin combined and clopidogrel |
| 246 | 3 | 1 | |a Effect of proton pump inhibitors on the risk of net clinical adverse events in patients with acute coronary syndrome receiving aspirin combined and clopidogrel |
| 264 | 1 | |c 2019-05-15 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:FAN Peng;LI Yi;WANG He-yang;LI Jing;QIU Miao-han;ZHAO Wei-chao;FANG Chu-ai;HAN Ya-ling;School of Life Sciences and Biopharmaceutics,Shenyang Pharmaceutical University | ||
| 520 | |a 目的探讨质子泵抑制剂(PPIs)对服用阿司匹林联合氯吡格雷的急性冠脉综合征(ACS)患者净临床不良事件(NACE)发生风险的影响。方法选取自2012年1月至2014年3月一项前瞻性、多中心、大规模注册登记研究冠心病抗血小板治疗优选方案(OPT-CAD)入选的服用氯吡格雷联合阿司匹林满1年的5 228例ACS患者为研究对象。根据是否服用了PPIs,将所有患者分为联用PPIs组(n=1 816)与未联用PPIs组(n=3 412)。以12个月内的净临床不良事件(NACE,包括全部心肌梗死、缺血性卒中和全部的出血事件的复合终点)为主要终点,以12个月内的NACE事件的组成成分以及出血学术研究联合会(BARC)定义的出血事件(BARC 2～5型)为次要终点。比较两组患者一般资料、出院后用药情况及临床结局。结果联用PPIs组患者年龄、估计的肾小球滤过率、左室射血分数及消化系统病史、消化道溃疡比例要高于未联用PPIs组,两组比较,差异均有统计学意义(P<0.05)。联用PPIs组的β受体阻滞剂和血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂的使用比例要高于未联用PPIs组,两组比较,差异均有统计学意义(P<0.05)。两组患者12个月NACE事件发生率、12个月缺血事件、心肌梗死、缺血性卒中、全部出血、BARC 2～5型出血方面比较,差异均无统计学意义(P>0.05)。结论 PPIs对服用阿司匹林联合氯吡格雷的ACS患者NACE发生风险没有影响。 | ||
| 520 | |a Objective To investigate the effect of proton pump inhibitors(PPIs)on net adverse clinical events(NACE)in patients with acute coronary syndrome(ACS)receiving aspirin and clopidogrel.Methods From January 2012 to March 2014,5 228 ACS patients who had been taking clopidogrel combined with aspirin for one year and who were enrolled in the optimal antiplatelet therapy for coronary heart disease(OPT-CAD)in a prospective,multi-center,large-scale registry study were selected as subjects.All patients were divided into the combination PPIs group(n=1 816)and not combination PPIs group(n=3 412)according to whether PPIs was administered.The primary end point was the NACE(including myocardial infarction,stroke,and all bleeding and major bleeding) within 12 months,and the secondary end point was the components of NACE events within 12 months and bleeding events(BARC type 2-5)defined by the academic research consortium(BARC).General data,drug use after discharge and clinical outcomes were compared between the two groups.Results Age,estimated glomerular filtration rate,left ventricular ejection fraction,history of digestive system,peptic ulcer rate in the combination PPIs group were higher than those in the not combination PPIs group,and the differences between the two groups were statistically significant(P<0.05).Beta blockers and angiotensin converting enzyme inhibitor/angiotensin Ⅱ receptor blockers use ratio in the combination PPIs group was higher than that in the not combination group(P<0.05).There were no statistically significant differences between the two groups in 12-month NACE event incidence,12-month ischemic event,myocardial infarction,ischemic stroke,total hemorrhage and BARC type 2-5 hemorrhage(P>0.05).Conclusion PPIs do not effect the risk of NACE in ACS patients treated with aspirin and clopidogrel. | ||
| 610 | 2 | 4 | |a 沈阳药科大学生命科学与生物制药学院 |
| 610 | 2 | 4 | |a 北部战区总医院心血管内科 |
| 650 | 4 | |a 心脏、血管（循环系）疾病 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Cardiovascular System Disease | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 急性冠脉综合征 | |
| 650 | 4 | |a 质子泵抑制剂 | |
| 650 | 4 | |a 氯吡格雷 | |
| 650 | 4 | |a 净临床不良事件 | |
| 650 | 4 | |a Acute coronary syndrome | |
| 650 | 4 | |a Proton pump inhibitors | |
| 650 | 4 | |a Clopidogrel | |
| 650 | 4 | |a Net adverse clinical events | |
| 700 | 0 | |a 李毅 |4 oth | |
| 700 | 0 | |a 王贺阳 |4 oth | |
| 700 | 0 | |a 李晶 |4 oth | |
| 700 | 0 | |a 裘淼涵 |4 oth | |
| 700 | 0 | |a 赵惟超 |4 oth | |
| 700 | 0 | |a 方楚嫒 |4 oth | |
| 700 | 0 | |a 韩雅玲 |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Lin chuang jun yi za zhi |d Liao ning sheng chen yang shi, 1991 |g (2019), 05 vom: 15. Mai, Seite 463-465+471 |h Online-Ressource |w (DE-627)CAJ075082403 |w (DE-600)2990629-5 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:05 |g day:15 |g month:05 |g pages:463-465+471 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=JYGZ201905007 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=JYGZ201905007 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 临床军医杂志 |d 辽宁省沈阳市 |h Online-Ressource |w (DE-627)CAJ075082403 |w (DE-600)2990629-5 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 05 |b 15 |c 05 |h 463-465+471 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 05 |b 15 |c 05 |h 463-465+471 | ||
| 980 | |2 11 |1 01 |x 0001 |b 650240464 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 02-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=JYGZ201905007 | ||